NuCana plc
NCNAHealthcare|Biotechnology|GB
$0.94
+0.00 (+0.40%)
DCF Value
$14.72
Tangible Book / Share
$4.29
Cash / Share
$4.63
Analyst Consensus
Buy8 analysts
Strong Buy
0
Buy
7
Hold
1
Sell
0
Strong Sell
0
Rating Trend
Jul 24
4 buy · 1 hold · 0 sell
Aug 24
5 buy · 2 hold · 0 sell
Sep 24
5 buy · 2 hold · 0 sell
Oct 24
5 buy · 2 hold · 0 sell
Nov 24
5 buy · 2 hold · 0 sell
Dec 24
2 buy · 2 hold · 0 sell
Jan 25
1 buy · 2 hold · 0 sell
Feb 25
1 buy · 2 hold · 0 sell
Mar 25
1 buy · 2 hold · 0 sell
Apr 25
1 buy · 2 hold · 0 sell
May 25
1 buy · 2 hold · 0 sell
Jun 25
0 buy · 1 hold · 0 sell
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Oppenheimer | maintain | Outperform | Aug 19, 2024 |
| Oppenheimer | maintain | Outperform | Jul 23, 2024 |
| Oppenheimer | maintain | Outperform | Jul 22, 2024 |
| Oppenheimer | maintain | Outperform | Apr 1, 2024 |
| Oppenheimer | maintain | Outperform | Nov 21, 2023 |
| Truist Securities | maintain | Buy | Sep 6, 2023 |
| Oppenheimer | maintain | Outperform | Aug 18, 2023 |
| Oppenheimer | maintain | Outperform | May 22, 2023 |
| Jefferies | maintain | Buy | Sep 22, 2022 |
| Cowen & Co. | downgrade | Outperform →Market Perform | Mar 3, 2022 |
| HC Wainwright & Co. | maintain | Buy | Nov 24, 2021 |
| HC Wainwright & Co. | maintain | Buy | Dec 1, 2020 |
| HC Wainwright & Co. | maintain | Buy | Nov 24, 2020 |
| Truist Securities | maintain | Buy | Oct 22, 2020 |
| HC Wainwright & Co. | maintain | Buy | Aug 21, 2020 |
| Oppenheimer | maintain | Outperform | Jul 24, 2020 |
| H.C. Wainwright | maintain | Buy | Mar 11, 2020 |
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2020 |
| H.C. Wainwright | maintain | Buy | Nov 15, 2019 |
| H.C. Wainwright | maintain | Buy | Aug 19, 2019 |
| PiperJaffray | maintain | Overweight | Oct 19, 2018 |
| Cowen & Co. | maintain | Outperform | Oct 23, 2017 |
| Citigroup | maintain | Buy | Oct 23, 2017 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-2.65| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.99 | $-2.65 | — | — |
| May 14, 2026 | $-1.25 | $-2.64 | — | — |
| Mar 19, 2026 | $-1.47 | $-2.69 | — | — |
| Nov 13, 2025 | $-0.10 | $-2.69 | — | — |
| Aug 20, 2025 | $-0.16 | $-2.75 | — | — |
| Jun 3, 2025 | $-5.17 | $-0.01 | — | — |
| Mar 20, 2025 | $-64.00 | $-486.00 | — | — |
| Nov 25, 2024 | $-456.00 | $-3.47 | — | — |
News
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
EDINBURGH, United Kingdom, Sept. 30, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the European Patent Office (“EPO”) has granted an important patent covering the composition of matter for NUC-7738.
Sep 30, 2026globenewswire.com
NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update
Final Data from Phase 2 Expansion Study of NUC-7738 Remains on Track for 2026 Advancing Additional Indications and Combination Strategies for NUC-7738 Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) today announced financial results for the second quarter ended June 30, 2026 and provided an update on its clinical development program with its two lead anti-cancer medicines. “NuCana continue…
Aug 13, 2026globenewswire.com